ICPT Stock Overview
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada.
Intercept Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$16.82|
|52 Week High||US$22.36|
|52 Week Low||US$11.60|
|1 Month Change||0.54%|
|3 Month Change||9.50%|
|1 Year Change||0.72%|
|3 Year Change||-80.37%|
|5 Year Change||-84.97%|
|Change since IPO||-13.30%|
Recent News & Updates
Intercept: Increase Of Ocaliva Sales And A Few Catalysts
Final data from the phase 3 REGENERATE study, using Ocaliva for the treatment of patients with NASH fibrosis, is expected any day now. If all goes well with clinical data, Intercept expects a pre-submission meeting with the FDA in June of 2022. Results from the phase 3 REVERSE study using Ocaliva for the treatment of patients with compensated cirrhosis due to NASH are expected in Q3 of 2022. Two studies are being done testing the fixed dose combination of Ocaliva and bezafibrate for the treatment of patients with primary biliary cholangitis. Licensing deal made with Advanz Pharma for Ocaliva brought in $405 million as an upfront payment and the potential to earn $45 million upon a condition being met; from there, it will be eligible for royalties on net sales.
Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
Intercept Pharmaceuticals, Inc. ( NASDAQ:ICPT ) shareholders will have a reason to smile today, with the analysts...
|ICPT||US Biotechs||US Market|
Return vs Industry: ICPT exceeded the US Biotechs industry which returned -22.1% over the past year.
Return vs Market: ICPT exceeded the US Market which returned -13.2% over the past year.
|ICPT Average Weekly Movement||10.8%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: ICPT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ICPT's weekly volatility (11%) has been stable over the past year.
About the Company
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development.
Intercept Pharmaceuticals Fundamentals Summary
|ICPT fundamental statistics|
Is ICPT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ICPT income statement (TTM)|
|Cost of Revenue||US$3.05m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.30|
|Net Profit Margin||-18.44%|
How did ICPT perform over the long term?See historical performance and comparison
Is Intercept Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ICPT ($16.82) is trading below our estimate of fair value ($349.56)
Significantly Below Fair Value: ICPT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ICPT is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Biotechs industry average.
PE vs Market: ICPT is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ICPT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ICPT has negative assets, so we can't compare its Price-To-Book Ratio to the US Biotechs industry average.
How is Intercept Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ICPT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: ICPT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ICPT's is expected to become profitable in the next 3 years.
Revenue vs Market: ICPT's revenue (22.3% per year) is forecast to grow faster than the US market (7.7% per year).
High Growth Revenue: ICPT's revenue (22.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ICPT's Return on Equity is forecast to be high in 3 years time
How has Intercept Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ICPT is currently unprofitable.
Growing Profit Margin: ICPT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ICPT is unprofitable, but has reduced losses over the past 5 years at a rate of 18.2% per year.
Accelerating Growth: Unable to compare ICPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ICPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: ICPT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Intercept Pharmaceuticals's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ICPT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ICPT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ICPT has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ICPT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ICPT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ICPT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Intercept Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ICPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ICPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ICPT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ICPT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ICPT has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jerry Durso (53 yo)
Mr. Jerome B. Durso, also known as Jerry, has been President and Chief Executive Officer of Intercept Pharmaceuticals, Inc. since January 1, 2021 and serves as its Director since May 27, 2021. Mr. Durso se...
CEO Compensation Analysis
Compensation vs Market: Jerry's total compensation ($USD7.87M) is above average for companies of similar size in the US market ($USD2.69M).
Compensation vs Earnings: Jerry's compensation has increased whilst the company is unprofitable.
Experienced Management: ICPT's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: ICPT's board of directors are considered experienced (8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Intercept Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Intercept Pharmaceuticals, Inc.
- Ticker: ICPT
- Exchange: NasdaqGS
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$493.831m
- Shares outstanding: 29.71m
- Website: https://www.interceptpharma.com
Number of Employees
- Intercept Pharmaceuticals, Inc.
- 10 Hudson Yards
- 37th Floor
- New York
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/25 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.